Dipeptidyl Peptidase IV Inhibitors for Nonalcoholic Fatty Liver Disease - Systematic Review and Metanalysis

Title:Dipeptidyl Peptidase IV Inhibitors for Nonalcoholic Fatty Liver Disease - Systematic Review and Metanalysis

Volume: 17 Issue: 5

Author(s): Lucas Ribeiro dos Santos*, Marcio Luis Duarte, Maria Stella Peccin, Antônio Ricardo de Toledo Gagliardi and Tamara Melnik

Affiliation:

• Department of Internal Medicine, Faculty of Medical Sciences of Santos - Lusiada University, Santos/SP, Oswaldo Cruz St, 179 - Boqueirão, Santos - SP, 11015-300,Brazil

Keywords: Dipeptidyl-Peptidase IV inhibitors, fatty liver, steatohepatitis, type 2 diabetes mellitus, obesity, systematic review.

Abstract: Introduction: Hepatic steatosis is a frequent condition that afflicts, especially, obese and insulin-resistant patients. Diagnosis is usually made through imaging tests. Despite the high prevalence and risk of complications, there is no specific treatment approved, though a vast number of medications have been tested.

Objective: This study aimed to determine the efficacy of dipeptidyl peptidase IV inhibitors (i DPP- IV) in the treatment of NAFLD.

Methods: We searched the electronic databases of the Cochrane Library, MEDLINE, EMBASE, and LILACS, as well as reference lists of the included studies and grey literature; 9 studies were selected for inclusion.

Results: 7 studies were used for metanalysis for 3 outcomes. i DPP-IV showed an ALT-reducing power of MD -10.83 (95% CI 35.23 to 13.57) at 3 months and MD -9.27 (95% CI 10.92 to -7.62) at 6 months of intervention, as well as a reduction of hepatic steatosis via MRI of SMD 0.10 (95% CI 0.31 to 0.50); the overall incidence of adverse events was very low. The studies were considered of low and very low quality by the GRADE evaluation.

Conclusion: Because of the overall poor quality of the studies and heterogeneity of the population analyzed, i DPP-IV did not show efficacy on inflammatory markers or fibrosis in patients with NAFLD.

Cite this article as:

dos Santos Ribeiro Lucas *, Duarte Luis Marcio , Peccin Stella Maria , Gagliardi Ricardo de Toledo Antônio and Melnik Tamara , Dipeptidyl Peptidase IV Inhibitors for Nonalcoholic Fatty Liver Disease - Systematic Review and Metanalysis, Current Diabetes Reviews 2021; 17 (5) : e101120187811 . https://dx.doi.org/10.2174/1573399816999201110195634

DOI https://dx.doi.org/10.2174/1573399816999201110195634	Print ISSN 1573-3998
Publisher Name Bentham Science Publisher	Online ISSN 1875-6417